Exact Sciences’ (EXAS) “Outperform” Rating Reiterated at William Blair

William Blair reissued their outperform rating on shares of Exact Sciences (NASDAQ:EXAS) in a research note published on Thursday morning,RTT News reports.

Several other equities analysts have also issued reports on EXAS. Piper Sandler lowered their price target on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Canaccord Genuity Group lowered their price target on Exact Sciences from $95.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Sanford C. Bernstein lifted their price objective on Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Robert W. Baird reduced their price objective on Exact Sciences from $70.00 to $67.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, Benchmark reiterated a “buy” rating and issued a $65.00 price objective on shares of Exact Sciences in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $72.06.

Exact Sciences Price Performance

EXAS opened at $49.26 on Thursday. The stock has a 50-day moving average price of $54.91 and a 200-day moving average price of $60.01. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The firm has a market cap of $9.15 billion, a PE ratio of -8.84 and a beta of 1.24. Exact Sciences has a 1 year low of $40.62 and a 1 year high of $79.62.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.23. The firm had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. Sell-side analysts predict that Exact Sciences will post -0.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exact Sciences

A number of large investors have recently made changes to their positions in EXAS. AMF Tjanstepension AB bought a new position in shares of Exact Sciences during the 3rd quarter valued at approximately $724,000. Creative Planning grew its stake in shares of Exact Sciences by 14.8% during the 3rd quarter. Creative Planning now owns 38,060 shares of the medical research company’s stock valued at $2,593,000 after acquiring an additional 4,906 shares during the period. Blue Trust Inc. grew its stake in shares of Exact Sciences by 61.0% during the 3rd quarter. Blue Trust Inc. now owns 5,220 shares of the medical research company’s stock valued at $356,000 after acquiring an additional 1,978 shares during the period. Sequoia Financial Advisors LLC bought a new position in shares of Exact Sciences during the 3rd quarter valued at approximately $569,000. Finally, Signaturefd LLC grew its stake in shares of Exact Sciences by 53.7% during the 3rd quarter. Signaturefd LLC now owns 1,652 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 577 shares during the period. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.